{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:18:57Z","timestamp":1777918737140,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[1997,5,1]],"date-time":"1997-05-01T00:00:00Z","timestamp":862444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[1997,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aims and background<\/jats:title>\n                    <jats:p>\n                      We investigated the efficacy and tolerability of two doses of paclitaxel, 175 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and 135 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , over a 3-hr infusion, without prophylactic G-CSF, in heavily pretreated patients with anthracycline-resistant breast cancer. Although paclitaxel may share with anthracyclines a common mechanism of drug resistance, there is evidence that the two drugs are not completely cross resistant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From July 1994 to January 1996, 42 patients were treated every 3 weeks, for a maximum of 6 cycles; paclitaxel dose was established according to pretreatment extension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 41 assessable patients we observed 9 partial responses, for an overall response rate of 22% (95% CI, 10\u201334%). There was no difference in response rate between the two dose levels. Median duration of response was 9 months, median time to progression 5 months, and median survival 9 months. The dose-limiting toxicity was neutropenia, which was grade 3\u20134 in 40% (135 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and 62% (175 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) of the patients (P = 0.28); neutropenic fever occurred in 24% of the patients, without significant differences between the two dose levels. Other toxicity was mild to moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Paclitaxel at doses of 175 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or 135 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      is active and well tolerated in advanced breast cancer patients resistant to anthracyclines. The prophylactic use of colony-stimulating factors seems appropriate in heavily pretreated patients given the higher dose level.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/030089169708300307","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T05:33:42Z","timestamp":1523943222000},"page":"661-664","source":"Crossref","is-referenced-by-count":6,"title":["Paclitaxel Activity in Anthracycline Refractory Breast Cancer Patients"],"prefix":"10.1177","volume":"83","author":[{"given":"Patrizia","family":"Vici","sequence":"first","affiliation":[{"name":"II Department of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Di Lauro","sequence":"additional","affiliation":[{"name":"II Department of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Conti","sequence":"additional","affiliation":[{"name":"II Department of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Capomolla","sequence":"additional","affiliation":[{"name":"II Department of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Gionfra","sequence":"additional","affiliation":[{"name":"II Department of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Amodio","sequence":"additional","affiliation":[{"name":"II Department of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Lopez","sequence":"additional","affiliation":[{"name":"II Department of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1997,5,1]]},"reference":[{"key":"bibr1-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.2056"},{"key":"bibr2-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.3.5.2646163"},{"key":"bibr3-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.97.1.30"},{"key":"bibr4-030089169708300307","first-page":"93","volume":"13","author":"Chervinsky D.S.","year":"1993","journal-title":"Anticancer Res."},{"key":"bibr5-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.55"},{"key":"bibr6-030089169708300307","first-page":"134","volume":"14","author":"Currow D.","year":"1995","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"bibr7-030089169708300307","first-page":"156","volume":"16","author":"Deuchars K.L.","year":"1989","journal-title":"Semin. Oncol."},{"key":"bibr8-030089169708300307","first-page":"276","volume-title":"In: Cancer. Principles & practice of oncology","author":"De Vita V.T.","year":"1993"},{"key":"bibr9-030089169708300307","first-page":"669","volume-title":"In: Diseases of the breast","author":"Flamm Honig S.","year":"1996"},{"key":"bibr10-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00398-3"},{"key":"bibr11-030089169708300307","first-page":"29","volume":"21","author":"Gianni L.","year":"1994","journal-title":"Semin. Oncol."},{"key":"bibr12-030089169708300307","first-page":"515","volume":"69","author":"Gupta R.S.","year":"1985","journal-title":"Cancer Treat. Rep."},{"key":"bibr13-030089169708300307","first-page":"94","volume":"12","author":"Holmes F.A.","year":"1993","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"bibr14-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.24.1797-a"},{"key":"bibr15-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"bibr16-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(84)90025-1"},{"key":"bibr17-030089169708300307","first-page":"33","volume":"13","author":"Mick R.","year":"1989","journal-title":"Treat."},{"key":"bibr18-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"bibr19-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1858"},{"key":"bibr20-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1943"},{"key":"bibr21-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.9.696"},{"key":"bibr22-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90476-T"},{"key":"bibr23-030089169708300307","first-page":"247","volume":"1","author":"Seidman A.D.","year":"1995","journal-title":"Clin. Cancer, Res."},{"key":"bibr24-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1152"},{"key":"bibr25-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2575"},{"key":"bibr26-030089169708300307","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.20.1685"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089169708300307","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089169708300307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:45:03Z","timestamp":1777661103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089169708300307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,5]]}},"alternative-id":["10.1177\/030089169708300307"],"URL":"https:\/\/doi.org\/10.1177\/030089169708300307","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,5]]}}}